Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma.

ABSTRACT:

Purpose

There is no standard-of-care systemic therapy for metastatic adenoid cystic carcinoma (ACC), and its management remains challenging. This study aimed to evaluate treatment patterns and disease outcomes in patients with metastatic head and neck ACC.

Methods

We conducted a retrospective analysis of patients diagnosed with metastatic head and neck ACC between January 2005 and December 2023.

Results

A total of 51 patients were included in the study, of whom 36 (70.6%) received at least one line of systemic treatment. The median overall survival (OS) for the entire cohort was 29.21 months. Patients with lung metastases had significantly longer OS compared to those without (44.52 vs. 11.04 months, p = 0.008). The median OS for patients who received at least one line

SUBMITTER: Bolek H 

PROVIDER: S-EPMC12481798 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature